Effectiveness and safety of exenatide in Korean patients with type 2 diabetes inadequately controlled with oral hypoglycemic agents: an observational study in a real clinical practice

Table 3 Adjusted potential variables for the prediction of the HbA1c responses according to the stratified classification

	HbA1c reduction ≥0.6%		HbA1c <7.5%		HbA1c reduction ≥9.8% from baseline
	OR (95% CI)	P	OR (95% CI)	P	OR (95% CI)	P
Male sex	1.47 (0.94–2.29)	0.09	Not determined		1.40 (0.90–2.15)	0.13
HbA1c ≥8.5%	3.13 (1.95–5.04)	<0.001	0.13 (0.08–0.22)	<0.001	2.36 (1.48–3.77)	<0.001
FPG ≥160 mg/dL	1.60 (1.01–2.54)	0.047	0.58 (0.35–0.97)	0.037	1.47 (0.93–2.34)	0.10
Duration of diabetes ≥5 years	0.997 (0.995–1.000)	0.053	0.994 (0.991–0.997)	<0.001	0.997 (0.994–1.000)	0.043
Number of previous antidiabetic medication (2 vs. 0 or 1)	1.07 (0.67–1.71)	0.79	0.91 (0.52–1.58)	0.74	1.28 (0.80–2.05)	0.31

Abbreviations: OR odd ratio, HbA1c Hemoglobin A1c, FPG Fasting plasma glucose
Multivariate logistic regression test; References of dependent variables in each stratum, Group 2, Group B, and group II, respectively

ISSN: 1472-6823